01451nam 2200397Ia 450 991069899920332120090609141910.0(CKB)5470000002397879(OCoLC)379067338(EXLCZ)99547000000239787920090609d1999 ua 0enguran|||||||||txtrdacontentcrdamediacrrdacarrierGuidance for industry[electronic resource] public health issues posed by the use of nonhuman primate xenografts in humansRockville, MD :U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,[1999]i, 7 p digital, PDF fileTitle from PDF title page (viewed on June 9, 2009)."April 1999".Includes bibliographic references (pages 6-7).Guidance for industry XenograftsGovernment policyUnited StatesPrimatesGovernment policyUnited StatesMedical policyUnited StatesXenograftsGovernment policyPrimatesGovernment policyMedical policyCenter for Biologics Evaluation and Research (U.S.)GPOGPOBOOK9910698999203321Guidance for industry3434577UNINA00973nam 2200277 450 99669828090331620260308114129.020260113d1978----km y0itay5003 baitaITy 00 yOrdine del giorno, aumento del capitale sociale e poteri dell'assembleacon un cenno ai cc.dd. versamenti in conto capitaleGiovanni GrippoMilanoGiuffrè1978612-618 p.24 cmTitolo della copertinaEstratto da: Giurisprudenza commerciale, anno 5, fasc. 4 (1978)Società di capitaliCapitale socialeAumentiBNCF346.45066GRIPPO,Giovanni227064ITcbaREICAT996698280903316XVI.7.Misc. 14341453 FBUOXVI.7.Misc.BKFBUOOrdine del giorno, aumento del capitale sociale e poteri dell'assemblea4523571UNISA